AU2011292119B2 - Anti-cancer adenoviruses - Google Patents

Anti-cancer adenoviruses Download PDF

Info

Publication number
AU2011292119B2
AU2011292119B2 AU2011292119A AU2011292119A AU2011292119B2 AU 2011292119 B2 AU2011292119 B2 AU 2011292119B2 AU 2011292119 A AU2011292119 A AU 2011292119A AU 2011292119 A AU2011292119 A AU 2011292119A AU 2011292119 B2 AU2011292119 B2 AU 2011292119B2
Authority
AU
Australia
Prior art keywords
orf3
cells
infected
carcinoma
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2011292119A
Other languages
English (en)
Other versions
AU2011292119A1 (en
Inventor
Clodagh O'shea
Colin Powers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Salk Institute for Biological Studies
Original Assignee
Salk Institute for Biological Studies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salk Institute for Biological Studies filed Critical Salk Institute for Biological Studies
Publication of AU2011292119A1 publication Critical patent/AU2011292119A1/en
Application granted granted Critical
Publication of AU2011292119B2 publication Critical patent/AU2011292119B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0679—Cells of the gastro-intestinal tract
    • C12N5/068—Stem cells; Progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2011292119A 2010-08-16 2011-08-16 Anti-cancer adenoviruses Active AU2011292119B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37421510P 2010-08-16 2010-08-16
US61/374,215 2010-08-16
PCT/US2011/048005 WO2012024350A2 (en) 2010-08-16 2011-08-16 Anti-cancer adenoviruses

Publications (2)

Publication Number Publication Date
AU2011292119A1 AU2011292119A1 (en) 2013-02-28
AU2011292119B2 true AU2011292119B2 (en) 2015-06-11

Family

ID=45605646

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011292119A Active AU2011292119B2 (en) 2010-08-16 2011-08-16 Anti-cancer adenoviruses

Country Status (10)

Country Link
US (1) US9187733B2 (https=)
EP (1) EP2606137B1 (https=)
JP (1) JP5905460B2 (https=)
KR (1) KR101667094B1 (https=)
CN (1) CN103180448B (https=)
AU (1) AU2011292119B2 (https=)
BR (1) BR112013003579A2 (https=)
CA (1) CA2807778C (https=)
SG (1) SG187785A1 (https=)
WO (1) WO2012024350A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG187785A1 (en) * 2010-08-16 2013-03-28 Salk Inst For Biological Studi Anti-cancer adenoviruses
CA3215250A1 (en) * 2012-03-13 2013-09-19 Salk Institute For Biological Studies Selective cell targeting using adenovirus and chemical dimers
AU2014236207B2 (en) 2013-03-14 2019-05-23 Salk Institute For Biological Studies Oncolytic adenovirus compositions
KR20250081944A (ko) 2014-09-24 2025-06-05 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양 살상 바이러스 및 이의 사용방법
EP3359175B1 (en) 2015-10-05 2020-09-16 Salk Institute for Biological Studies Synthetic adenoviruses with tropism to damaged tissue for use in promoting wound repair and tissue regeneration
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
EP4155411A1 (en) 2016-02-23 2023-03-29 Salk Institute for Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
EP3532082A4 (en) 2016-12-12 2020-08-26 Salk Institute for Biological Studies SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES
MX2019013259A (es) 2017-05-08 2020-01-13 Gritstone Oncology Inc Vectores de neoantigeno de alfavirus.
MX2020010499A (es) 2018-04-09 2020-10-28 Salk Inst For Biological Studi Composiciones de adenovirus oncoliticas con propiedades aumentadas de replicacion.
MX2021014525A (es) * 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1083229A1 (en) * 1999-09-10 2001-03-14 Introgene B.V. Modified adenoviral vectors for use in gene therapy
US20020106382A1 (en) * 2000-07-14 2002-08-08 Young Charles S.H. Modified adenovirus and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA137094A (en) 1911-08-31 1911-11-28 Sheppe, Alice L. Cloth measuring and price calculating machine
FR2726285B1 (fr) * 1994-10-28 1996-11-29 Centre Nat Rech Scient Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
ES2210081T3 (es) * 1998-07-07 2004-07-01 Transgene S.A. Utilizacion de los marcos de lectura de la region e4 para la mejora de la expresion de genes.
WO2001090392A1 (en) * 2000-05-26 2001-11-29 Sumitomo Pharmaceuticals Company, Limited Novel recombinant adenovirus vector with relieved side effects
US20030220284A1 (en) 2002-02-22 2003-11-27 Patricia Yotnda Delivery of adenoviral DNA in a liposomal formulation for treatment of disease
EP1499332A4 (en) 2002-04-29 2006-12-06 Hadasit Med Res Service COMPOSITIONS AND METHODS FOR TREATING CANCER WITH A VIRAL ONCOLYTIC AGENT
EP1545627A4 (en) 2002-10-01 2006-12-27 Univ Duke TARGETED TUMOR THERAPY THROUGH THE USE OF RECOMBINANT ADENOVIRUS VECTORS FOR SELECTIVE REPLICATION IN HYPOXIC TUMOR REGIONS
US20050201978A1 (en) 2003-11-17 2005-09-15 Lipton James S. Tumor and infectious disease therapeutic compositions
JP2012504140A (ja) * 2008-09-26 2012-02-16 オーバーン・ユニバーシティ 非複製性ベクターワクチンの粘膜投与による鳥類の免疫処置
SG187785A1 (en) * 2010-08-16 2013-03-28 Salk Inst For Biological Studi Anti-cancer adenoviruses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1083229A1 (en) * 1999-09-10 2001-03-14 Introgene B.V. Modified adenoviral vectors for use in gene therapy
US20020106382A1 (en) * 2000-07-14 2002-08-08 Young Charles S.H. Modified adenovirus and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Goodrum FD et al, Journal of Virology, 1999, 73(9):7474-88. *
Shepard RN et al, Journal of Virology, 2003, 77(15):8593-5 *
Shepard RN et al, Journal of Virology, 2004, 78(18):9924-35 *

Also Published As

Publication number Publication date
KR101667094B1 (ko) 2016-10-17
WO2012024350A2 (en) 2012-02-23
BR112013003579A2 (pt) 2016-06-07
EP2606137B1 (en) 2018-08-01
CA2807778C (en) 2017-03-07
US20130243729A1 (en) 2013-09-19
KR20130126590A (ko) 2013-11-20
EP2606137A4 (en) 2014-01-08
CN103180448B (zh) 2017-04-12
CN103180448A (zh) 2013-06-26
SG187785A1 (en) 2013-03-28
EP2606137A2 (en) 2013-06-26
JP5905460B2 (ja) 2016-04-20
WO2012024350A3 (en) 2012-07-05
JP2013537426A (ja) 2013-10-03
CA2807778A1 (en) 2012-02-23
AU2011292119A1 (en) 2013-02-28
US9187733B2 (en) 2015-11-17

Similar Documents

Publication Publication Date Title
AU2011292119B2 (en) Anti-cancer adenoviruses
US12589128B2 (en) Oncolytic adenovirus compositions
Li et al. Adenovirus-mediated heat-activated antisense Ku70 expression radiosensitizes tumor cells in vitro and in vivo
KR100379174B1 (ko) DNA손상제및p53을포함하는조성물
WO2013138505A1 (en) Selective cell targeting using adenovirus and chemical dimers
AU2003226835B2 (en) Use of adenoviruses mutated in the VA genes for cancer treatment
Bertzbach et al. The adenovirus DNA-binding protein DBP
Schipper et al. Eradication of metastatic melanoma through cooperative expression of RNA-based HDAC1 inhibitor and p73 by oncolytic adenovirus
Nie et al. Gene therapy for colorectal cancer by an oncolytic adenovirus that targets loss of the insulin-like growth factor 2 imprinting system
Lee et al. Growth inhibitory effect on glioma cells of adenovirus-mediated p16/INK4a gene transfer in vitro and in vivo.
Roth et al. Gene replacement strategies for treating non-small cell lung cancer
Kaliberova et al. CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma
Ebara et al. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters
Graumann Studies on biodistribution and pharmacokinetics of capsid-modified adenoviral vectors
Beck Enhancing oncolytic adenovirus efficacy for the treatment of metastatic prostate cancer through combination with BET protein inhibitors
CN102108356B (zh) 新颖启动子及包含其之病毒载体
TWI391486B (zh) 新穎啟動子及包含其之病毒載體
van den Wollenberg Characterization of a replicating expanded-tropism oncolytic
Kallin Screening of pancreatic cancer cell lines with oncolytic adenovirus Ad5ΔE1ACR2ΔE1B19k (Ad5ΔΔ) in combination with chemotherapeutics
HK1071060B (en) Use of adenoviruses mutated in the va genes for cancer treatment
HK1080112A (en) Use of adenoviruses mutated in the va genes for cancer treatment
CN101822844A (zh) 肿瘤靶向分子化疗基因-病毒制剂SG500-dNKmut及构建方法和用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)